GHRH analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
=== Molecular profiles === Protein electrophoresis (general technique—not a specific test) Western blot (general technique—not a specific test) Liver function tests Polymerase chain reaction (DNA). DNA profiling is today possible with even very small quantities of blood: this is commonly used in forensic science, but is now also part of the diagnostic process of many disorders. Northern blot (RNA) Sexually transmitted diseases
Pharmaceutical form Chemical form Route of administration Stability Metabolism These concepts, which are discussed in detail in their respective titled articles, can be mathematically quantified and integrated to obtain an overall mathematical equation:
Because ovulation is triggered by a surge in estradiol levels at mid-cycle, estrogen exposure during elagolix therapy might be greater around this time in some women. In addition to its activity as a GnRH antagonist, elagolix is a weak to moderate inducer of CYP3A and an inhibitor of P-glycoprotein. As a result, elagolix may affect the metabolism and/or transport of other medications, and this may contribute to drug interactions with elagolix.
Sources: en.wikipedia.org
Women participated extensively in unconventional warfare, including in combat positions, in the Chinese Red Army during the revolutionary period, Chinese Civil War (1927–1949) and the Second Sino-Japanese War (1937–1945). After the establishment of the People's Republic of China, along with the People's Liberation Army (PLA)'s transition toward the conventional military organization, the role of women in the armed forces gradually reduced to support, medical, and logistics roles. It was considered a prestigious choice for women to join the military. Serving in the military opens up opportunities for education, training, higher status, and relocation to cities after completing the service. During the Cultural Revolution, military service was regarded as a privilege and a method to avoid the Down to the Countryside Movement. In the 1980s, the PLA underwent large-scale demobilization amid the reform and opening up, and women were discharged back to civilian society for economic development while the exclusion of women in the military expanded. In the 1990s, the PLA revived the recruitment of female personnel in regular military formations but primarily focused on non-combat roles at specialized positions. Most women were trained in areas such as academic/engineering, medics, communications, intelligence, cultural work, and administrative work, as these positions conform to the traditional gender roles. Women in the PLA were more likely to be cadets and officers instead of enlisted soldiers because of their specializations.
==== Fibrosis ==== In accordance with the known expression of αvβ6-integrin in early lung fibrosis, 68Ga-Trivehexin was used for PET/CT imaging of idiopathic pulmonary fibrosis (IPF). In explorative studies, 68Ga-Trivehexin could generate an IPF-specific PET signal while the same tissue areas were PET-negative using the standard metabolic PET tracer 18F-FDG. 68Ga-Trivehexin PET scans displayed an uptake of SUVmax = 5.53 in fibrotic lung areas and thus enabled clear differentiation of fibrotic from non-fibrotic lung tissue.
=== Ma–Me === Alan MacDiarmid (1927–2007), American-New Zealand chemist who discovered conductive polymers, 2000 Nobel Prize in Chemistry Carolina Henriette Mac Gillavry (1904–1993), Dutch chemist and crystallographer known for discoveries on the use of diffraction in crystallography Roderick MacKinnon (born 1956), American biophsicist known for work on ion channels; 2003 Nobel Prize in Chemistry Pierre Macquer (1718–1784), French chemist known for Dictionnaire de chymie Rudolph A. Marcus (1923–2026), Canadian chemist known for work on the theory of electron transfer reactions; 1992 Nobel Prize in Chemistry Jacob A. Marinsky (1918–2005), American chemist, co-discovered the element promethium Jean Charles Galissard de Marignac (1817–1894), Swiss chemist who discovered ytterbium and co-discovered gadolinium Vladimir Vasilevich Markovnikov (1838–1904), Russian chemist known for Markovnikov's rule describing addition reactions of hydrogen halides and alkenes Tobin J. Marks (born 1944), American inorganic chemist and materials scientist known for work in polymerization catalysts Alan G.
Sources: en.wikipedia.org
== Interactions == Sauvagine has been shown to interact with corticotropin releasing factor receptors 1 and 2, and (as with other CRF-related peptides) is also bound by the corticotropin-releasing factor binding protein.
After Cuenca, where they attended bullfights, the travelers proceeded to Loja to study the cinchona tree, the source of quinine. They spent nearly three weeks exploring the Amazon headwaters near Jaen, Peru, then crossed the Andes again near Cajamarca, where he spent five days visiting relics linked to the Inca ruler’s capture and execution by the Spanish, including the supposed execution stone and the room where Atahualpa offered gold for his freedom.. At this point, Humboldt’s measurement of Earth’s magnetic intensity provided a benchmark for future geomagnetic studies, as they crossed the magnetic equator. By October 1802, after extensive travel in the Andes, the expedition reached sea level at Trujillo and arrived in Lima on 23 October 1802. Humboldt’s impressions of Lima were largely unfavorable. In a letter dated January 18, 1803, addressed to the Governor of Jaén, he described Lima as having declined significantly compared to other South American cities such as Buenos Aires, Santiago de Chile, and Arequipa. He observed an absence of well-furnished homes and well-dressed women, attributing the city’s poverty to economic conditions and widespread gambling. Public amusements were limited to a theater and an attractive bullring. Humboldt noted that nighttime travel by carriage was hindered by stray dogs and donkey carcasses obstructing the streets. He criticized the prevalence of gambling and family separation, which he believed disrupted social cohesion, and remarked on the lack of large social gatherings.
=== Surgery === Plantar fasciotomy is a surgical treatment and the last resort for refractory plantar fasciitis pain. After six months of conservative treatment, surgery is considered a last resort. Minimally invasive and endoscopic approaches to plantar fasciotomy exist, but require a specialist. The availability of these surgical techniques was limited as of 2012. A 2012 study reported that 76% of endoscopic plantar fasciotomy patients had complete symptom relief and few complications (level IV evidence). Heel spur removal during plantar fasciotomy does not appear to improve surgical outcomes. Plantar heel pain may occur for multiple reasons. In select cases, surgeons may perform a release of the lateral plantar nerve alongside the plantar fasciotomy. Possible complications of plantar fasciotomy include nerve injury, instability of the medial longitudinal arch, fracture of the calcaneus, prolonged recovery time, infection, rupture of the plantar fascia, and failure to improve pain. Coblation surgery is proposed as an alternative surgical approach. Gastrocnemius recession is a surgical procedure that involves lengthening the gastrocnemius muscle to reduce tension in the Achilles tendon and plantar fascia. This technique improves the ankle's range of motion, reduces pain, and can help patients return to work, sports, and weight-bearing activities more comfortably. The procedure is particularly beneficial for individuals with limited ankle dorsiflexion due to tight calf muscles, which can exacerbate plantar fasciitis symptoms.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.